Framingham Risk Score Calculator Pdf Creator
Recent estimates indicate that 8 million adults in the United States have peripheral artery disease (PAD) and that its prevalence is increasing worldwide. Compared with persons without PAD, those with the disease have a 2- to 4-fold increased rate of cardiovascular events, even when cardiovascular disease (CVD) risk factors are taken into account. Statins, antiplatelet therapies, and antihypertensive therapies can reduce cardiovascular events in persons with PAD. Peripheral artery disease often presents with no or atypical symptoms but can be diagnosed noninvasively in clinicians’ offices by using the ankle–brachial index (ABI).
For these reasons, ABI screening and implementation of cardiovascular preventive therapy for persons with PAD could be expected to reduce cardiovascular morbidity and mortality. In this issue, Lin and colleagues report the results of a systematic review used to inform the updated U.S. Preventive Services Task Force (USPSTF) recommendation on ABI screening. The USPSTF concluded that the current evidence is insufficient to assess the balance of benefits and harms of PAD screening and recommended neither for nor against screening with the ABI. In contrast to the previous USPSTF recommendation on ABI screening published in 2005, the updated guidelines considered whether the ABI adds meaningfully to CVD risk prediction as measured by the Framingham Risk Score (FRS). Thus, the systematic review by Lin and colleagues includes assessment of 2 questions: Does the ABI provide clinically important prognostic information about CVD risk beyond that provided by the FRS, and does screening for PAD with the ABI followed by treatment of patients with the disease reduce cardiovascular event rates? At first, the USPSTF's conclusion may seem surprising.
Undiagnosed PAD is common, the ABI has excellent diagnostic and prognostic characteristics, and medications are available that decrease cardiovascular events in persons diagnosed with PAD. Currently, the ABI is used infrequently to screen for PAD in clinical practice in the United States, and the disease is commonly underdiagnosed. The PARTNERS (PAD Awareness, Risk, and Treatment: New Resources for Survival) study measured the ABI of patients in 350 primary care practices across the United States who were aged 70 years or older or aged 50 to 69 years with a history of diabetes mellitus or smoking. Of 6979 patients tested, 1865 (29%) had an ABI less than 0.9, which is consistent with PAD.
Of note, 45% of those with an ABI less than 0.9 had no history of clinically diagnosed PAD, and only 11% had classic symptoms of intermittent claudication. The remaining participants who tested positive for PAD were asymptomatic or had atypical leg symptoms. These types of PAD were more common among persons newly diagnosed with the disease, suggesting that the high prevalence of asymptomatic disease and atypical leg symptoms contributes to underdiagnosis.
Framingham Risk Score Chart
Consistent evidence shows that an ABI less than 0.9 is associated with increased all-cause mortality and cardiovascular morbidity and mortality compared with those in persons without PAD. Yet, Lin and colleagues found limited evidence to support adding the ABI to the FRS to predict risk for CVD.
Therefore, the ABI may not provide additional clinically meaningful predictive information beyond that attainable by the FRS. This observation explains, in part, why the USPSTF concluded that the current evidence is insufficient to assess the balance of benefits and harms of PAD screening and CVD risk assessment with the ABI in adults. To improve health and prevent cardiovascular events, ABI screening must identify a large number of individuals with an ABI less than 0.9 who are undertreated. In the PARTNERS study, 1040 of the 1865 participants found to have PAD (55%) had concomitant clinically evident CVD and 311 of the remaining 825 (38%) had diabetes. Of the 821 patients with newly diagnosed PAD, 365 (44%) had other CVD that was previously diagnosed and clinically evident and 150 (18%) had diabetes mellitus.
Thus, 515 of the 821 participants with newly diagnosed PAD (63%) had other indications for intensive treatment of cardiovascular risk factors. No randomized, controlled trials have assessed whether ABI screening followed by cardiovascular preventive therapies for all patients with PAD reduces cardiovascular event rates compared with usual care. The Aspirin for Asymptomatic Atherosclerosis trial used the ABI to screen 28 980 community-dwelling adults aged 50 to 75 years with no history of CVD. A total of 3350 participants diagnosed with PAD on the basis of ABI screening were randomly assigned to receive 100 mg of aspirin or placebo. No differences in the primary outcome of fatal or nonfatal cardiovascular events were seen between the aspirin and control groups at 8.2 years of follow-up (13.7 vs.
13.3 events per 1000 person-years). Similarly, all-cause mortality did not differ between the groups.
Thus, in this cohort, ABI screening followed by aspirin prescription for a random sample of patients with PAD did not reduce cardiovascular events or all-cause mortality. Several characteristics of Lin and colleagues’ systematic review are worth noting. First, by definition, screening applies only to individuals without signs or symptoms of disease. Thus, the authors limited their review to persons without leg symptoms. Yet, atypical leg symptoms are common in PAD and it is well-established that the disease is underdiagnosed in persons who are not asymptomatic.
Targeted ABI testing for patients with atypical leg symptoms may be beneficial but was not addressed in the review. Second, Lin and colleagues identified the Aspirin for Asymptomatic Atherosclerosis trial as a primary study that informed assessment of the benefits and harms of ABI screening; however, that trial used aspirin to prevent cardiovascular events in persons identified with PAD.
Recent evidence raises questions about the efficacy of aspirin for preventing cardiovascular events in patients with PAD. A study that evaluated the effectiveness of alternative or multiple cardiovascular prevention interventions might have found benefit associated with screening. Third, PAD is associated with increased rates of functional decline and mobility loss in addition to cardiovascular events.
The USPSTF did not address whether ABI screening can prevent mobility loss in persons found to have PAD. Dr Kirti KainSenior Lecturer, University of LeedsSeptember 12, 2013Absolute systolic ankle blood pressures versus ankle brachial indexWith reference to the editorial by McDermott it might be a global imperative to conduct ‘A definitive randomized, controlled trial to determine whether absolute systolic ankle blood pressures screening independent of systolic brachial blood pressures improves health outcomes in persons at risk for peripheral arterial disease and cardiovascular disease. Peripheral arterial disease can be defined by abnormally low and high ankle brachial index and both increase cardiovascular mortality. Majority of studies have defined peripheral arterial disease with ankle brachial index.
Mary McGrae McDermott, MDNorthwestern UniversityNovember 7, 2013ResponseFirst, Dr. Kain expresses concern that the ankle brachial index (ABI), a ratio of Doppler-recorded systolic pressures in the ankle and brachial arteries, does not distinguish between the independent predictive values of the systolic ankle and the systolic brachial blood pressure.
But because the ABI calculation requires measurement of both the ankle and the brachial systolic pressures, prior prospective studies relating the ABI to subsequent cardiovascular events and mortality have the ability to separately analyze the independent predictive value of the systolic ankle and brachial blood pressures for cardiovascular events and mortality. For example, a meta-analysis relating the ABI to cardiovascular events and mortality included 16 prospective studies, 48,295 participants, and 480,325 person years of follow-up (1). This meta-analysis alone provides a robust opportunity to evaluate the relative independent associations of the ABI, ankle systolic pressure, and brachial systolic pressure with cardiovascular events and mortality. Kain states that systolic blood pressure screening fails to identify more than half of individuals with undiagnosed diabetes. He implies that measuring the ankle systolic pressure may identify a greater number of individuals with undiagnosed diabetes.
Kain may be correct that an elevated ankle systolic pressure is more sensitive for identifying diabetes than an elevated brachial systolic pressure, neither test is likely to achieve optimal sensitivity as a diagnostic test for diabetes. For example, in the Multi-Ethnic Study of Atherosclerosis (MESA), most of the men and women with diabetes mellitus did not have an ABI 1.30, consistent with a high ankle pressure. Although further study is needed, these and other data suggest that most people with diabetes mellitus do not have an elevated ankle pressure (2,3). Third, given the high rate of diabetes and cardiovascular disease in South Asians (4), early diagnosis, treatment, and prevention of diabetes and cardiovascular disease in South Asians are public health imperatives. However, in 2013, relatively little is known about the utility of screening systolic ankle blood pressures for identifying individuals at high risk of cardiovascular events and preventing adverse outcomes.
The study by Kain et al supporting the hypothesis that elevated ankle pressures may be useful for diagnosing diabetes and cardiovascular disease in South Asians (5) employs a case-control study design, a relatively weak study design. Further study, including longitudinal prospective studies and randomized trials, is needed before large-scale screening with ankle systolic pressures in high-risk groups, such as South Asians, can be recommended. Ankle Brachial Index Collaboration. Ankle brachial Index Combined with Framingham Risk Score to Predict Cardiovascular Events and Mortality. JAMA 2008;300:197-208. McDermott MM, Liu K Criqui MH et al.
Ankle-brachial index and subclinical cardiac and carotid disease: The Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2005;162:33-41. Sutton-Tyrrell K, Venkitachalam L, Kanaya AM, et al. Relationship of ankle blood pressures to cardiovascular events in older adults. Stroke 2008;39:863-869.
Framingham Risk Calculator 2017
Tillin T, Hughes AD, Mayet J et al. The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbean. J Am Coll Cardiol 20-1786.
Kain K, Brockway M, Ishfaq T et al. Ankle pressures in UK South Asians with diabetes mellitus: A case control study. Heart 2013;99:614-619.